PARP1 and pachyonychia congenita: A comprehensive investigation of PARP inhibitors has not been paused, and over 80 PARP inhibitor treatment studies in PC patients, including a variety of monotherapies or combination regimens, are found in the database of ClinicalTrials.gov.